JDB175

N/A

Report date: 2022/06/27 14:06:21
NME

Base Information

Drug NameJDB175
Drug Alias NameJDB175
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsMultiple SclerosisLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple SclerosisLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A